NCT07654972RecruitingPhase 1
A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy
A Phase 1, Randomized, Placebo-Controlled, Single- and Multiple-Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy
Source: ClinicalTrials.gov · Last updated 15 Oct 2026
Brief summary (registry, in English)
The main purpose of this study is to understand how safe and well-tolerated LY4174794 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4174794 gets into the bloodstream and how long it takes the body to eliminate it. Participation in this study will last about 30 to 39 weeks (7 to 10 months).
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 116 (estimated)
- First submitted
- 12 Jun 2026
- Start date
- 24 Jun 2026
- Primary completion date
- Apr 2029
- Lead sponsor
- Eli Lilly and Company
- Diseases
- Obesity
- NCT number
- NCT07654972
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 116
- From 24 Jun 2026 to the primary completion date, Apr 2029
- 3 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Have a history or presence of cardiovascular, respiratory, hepatic, renal, GI, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study intervention, or of interfering with the interpretation of data
Other
- Is an individual of childbearing potential (IOCBP)
Who the study is looking for
- Are overtly healthy with no comorbidities related to body mass index (BMI), such as type 2 diabetes mellitus or unstable cardiovascular disease
- Are overweight with a BMI of ≥27 kilogram per meter square (kg/m²), or have obesity with a BMI of ≥30 kg/ m²
- Have had a self-reported stable weight for 3 months prior to screening
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Lilly Centre for Clinical Pharmacology Coordinator of this site? Confirm its status | Singapore | Singapore | Not yet recruiting |
| ICON Early Phase Services, LLC Coordinator of this site? Confirm its status | Salt Lake City | United States | Not yet recruiting |
| ICON Early Phase Services, LLC Coordinator of this site? Confirm its status | San Antonio | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.